Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

BackgroundThe COMPASSION-15 trial demonstrated that cadonilimab plus chemotherapy (CAD-CHM) confers clinical benefits over placebo plus chemotherapy (PLA-CHM) as a first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ)...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhifeng Zhou, Yanqing Yang, Shaofang Chen, Maojin You
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
cadonilimab
chemotherapy
cost-effectiveness
first-line treatment
HER2-negative
gastric or gastroesophageal junction adenocarcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1575627/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1575627/full

Similar Items